INFeD® improved the hemoglobin response to erythropoietic therapy in patients with documented INFeD® full Prescribing Information. Watson Pharma, Inc. 1 mL of INFeD provides 50 mg of elemental iron UpToDate (courtesy of Lexicomp), or the prescribing information. INFeD: INFeD is administered by intramuscular or intravenous injection. Before . during the acute phase of infectious renal disease (manufacturer’s information) . Therefore, the therapeutic prescription use of iron is usually compatible with.

Author: Gurr Tojakora
Country: Nepal
Language: English (Spanish)
Genre: History
Published (Last): 15 June 2004
Pages: 365
PDF File Size: 15.92 Mb
ePub File Size: 15.23 Mb
ISBN: 567-5-54267-921-2
Downloads: 56716
Price: Free* [*Free Regsitration Required]
Uploader: Dijora

Infants and Children 4 months and older weighing 10 to 15 kg. Administration of iron does not stimulate the production of red blood cells, nor does it correct abnormalities not caused by iron deficiency.

U.S. Prescribing Information Disclaimer

There is some concern that intravenously administered iron is not used appropriately by informaion body. DexFerrum is administered by intravenous injection only. If a informatjon infant experiences an adverse effect related to a maternally ingested drug, healthcare providers are encouraged to report the adverse effect to the FDA.

Minor It is important that iron stores be replete before beginning therapy with darbepoetin alfa due to increased iron utilization. Give DexFerrum test doses gradually over at least 5 minutes. Adults, Adolescents, and Children weighing 10 kg or more. Minor Inadequate iron stores will interfere with the therapeutic response to epoetin alfa e.

Some patients with chronic hepatic disease may also have hemochromatosis or moderate iron overload in hepatic tissues. See individual dosage if using total dose IV infusion methods. Adult men, Adolescent males, and Postmenopausal women. Specific guidelines for dosage adjustments in hepatic impairment are not available. Flushing and hypotension are more common following rapid intravenous administration; do not exceed recommended IV infusion rates.


Methoxy polyethylene glycol-epoetin beta: Too much iron can be toxic, and iron is not easily eliminated from the body. While the manufacturer recommends 25 mg 0. Furthermore, concomitant use of angiotensin-converting enzyme inhibitors may increase the risk for serious reactions to iron dextran.

A stable complex is formed that prevents iron from entering into further chemical reactions. Consult specialized references for amount of test dose to be given. Fatal reactions have occurred following the test dose of iron dextran and also have occurred after other doses when the test dose was tolerated.

However, iron imformation may develop, especially in children and menstruating or pregnant women, or as a result of the low copper diet recommended for Wilson’s disease. infedd

Iron dextran (INFeD)

The stability of iron dextran in TPN solutions has not been well established. Use of iron dextran in infants younger than 4 months of age and neonates is not recommended; there have been reports from other countries of an increased incidence of gram-negative sepsis e. Excess accumulation may occur if iron therapy is continued after the correction of the deficiency. Hemosiderosis secondary to long-term iron dextran treatment infoormation primarily been reported in patients with renal failure presrcibing dialysis.

In inofrmation second stage, macrophages ingest the iron dextran and enter the lymphatic system and eventually the blood. Inject via slow IV at a gradual rate not to exceed 50 mg 1 mL per minute for adults; take care to inject dosage very slowly in children and infants. Intramuscular or Intravenous dosage. Patients with a history of drug allergy may be at increased risk for anaphylactoid reactions.


According to the manufacturer, caution should be exercised if iron dextran is administered to a nursing mother.

Patients with a significant history of allergies e. The following are generally accepted limits in the treatment of iron-deficient patients. Parenteral iron supplement of ferric oxyhydroxide complexed with dextrans; rapidly repletes iron stores in deficiency from anemia or blood loss; sometimes associated with severe hypersensitivity.

Evaluate transferrin saturation and serum ferritin before and during epoetin alfa treatment. Infants 4 months and older weighing less than 5 kg. The liver is one of the main storage sites for iron, and some patients with chronic liver disease may have excessive iron storage.

INFeD (iron dextran) dose, indications, adverse effects, interactions from

Before administering therapeutic doses by any route, a test dose of of iron dextran should be given by the route and method of administration for which therapeutic doses are to be administered.

Some patients received epoetin in conjunction with parenteral iron. Do not administer iron during dimercaprol treatment. In the study of infants with the gestational age of about 28 weeks, a dose of 0. Major Deferasirox chelates iron and is indicated as a treatment of iron toxicity or overdose.

Therapy with iron should generally be delayed until 24 hours after the cessation of dimercaprol therapy. INFeD is administered by intramuscular or intravenous injection. Administer supplemental iron therapy when serum ferritin is Fosinopril: Patients with preexisting cardiac disease may have exacerbation of cardiovascular symptoms if adverse effects occur following iron dextran administration.